These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37533950)

  • 1. Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
    Baa AK; Sharma A; Bhaskar S; Biswas A; Thakar A; Kumar R; Jayant S; Aland G; D'Souza A; Jadhav V; Bharde A; Khandare J; Pramanik R
    Ecancermedicalscience; 2023; 17():1578. PubMed ID: 37533950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
    Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
    Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery.
    Payne K; Brooks JM; Taylor GS; Batis N; Noyvert B; Pan Y; Nankivell P; Mehanna H
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the epithelial-mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma.
    Payne K; Brooks J; Batis N; Taylor G; Nankivell P; Mehanna H
    Head Neck; 2022 Nov; 44(11):2545-2554. PubMed ID: 35932094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
    Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
    Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour cells in metastatic head and neck cancers.
    Kulasinghe A; Perry C; Jovanovic L; Nelson C; Punyadeera C
    Int J Cancer; 2015 Jun; 136(11):2515-23. PubMed ID: 25111594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma.
    Liu K; Chen N; Wei J; Ma L; Yang S; Zhang X
    Oncol Rep; 2020 May; 43(5):1525-1535. PubMed ID: 32323844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC.
    Rahman MM; Hossain MM; Islam S; Ahmed R; Majumder M; Dey S; Kawser M; Sarkar B; Himu MER; Chowdhury AA; Ahmed S; Biswas S; Anwar MM; Hussain MJ; Kumar Shil R; Baidya S; Parial R; Islam MM; Bharde A; Jayant S; Aland G; Khandare J; Uddin SB; Noman ASM
    BMC Mol Cell Biol; 2024 Feb; 25(1):4. PubMed ID: 38336617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.
    Grisanti S; Almici C; Consoli F; Buglione M; Verardi R; Bolzoni-Villaret A; Bianchetti A; Ciccarese C; Mangoni M; Ferrari L; Biti G; Marini M; Ferrari VD; Nicolai P; Magrini SM; Berruti A
    PLoS One; 2014; 9(8):e103918. PubMed ID: 25105871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma.
    Bueno de Oliveira T; Camila Braun A; Ribaldo Nicolau U; Ali Abdallah E; da Silva Alves V; Hugo Fonseca de Jesus V; Fernando Calsavara V; Paulo Kowaslki L; Domingos Chinen LT
    Oral Oncol; 2021 Oct; 121():105480. PubMed ID: 34403888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor Cells Correlate With Prognosis in Head and Neck Squamous Cell Carcinoma.
    Zhou S; Wang L; Zhang W; Liu F; Zhang Y; Jiang B; Wang J; Yuan H
    Technol Cancer Res Treat; 2021; 20():1533033821990037. PubMed ID: 33641530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
    Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
    BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
    Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment.
    Poellmann MJ; Bu J; Kim D; Iida M; Hong H; Wang AZ; Wheeler DL; Kimple RJ; Hong S
    Cancer Lett; 2023 May; 562():216187. PubMed ID: 37068555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook.
    Tinhofer I; Staudte S
    Expert Rev Mol Diagn; 2018 Oct; 18(10):897-906. PubMed ID: 30199647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma.
    Tada H; Takahashi H; Kuwabara-Yokobori Y; Shino M; Chikamatsu K
    Oral Oncol; 2020 Mar; 102():104558. PubMed ID: 32044652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.